Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.

@article{Hanania2017LongtermSA,
  title={Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.},
  author={Nicola Alexander Hanania and Donald P. Tashkin and Edward M. Kerwin and James F Donohue and Michael Denenberg and Denis E O'Donnell and Dean S. Quinn and Shahid Siddiqui and Chad Orevillo and Andrea Maes and Colin Reisner},
  journal={Respiratory medicine},
  year={2017},
  volume={126},
  pages={
          105-115
        }
}
BACKGROUND The long-term safety and efficacy of a novel Co-Suspension™ Delivery Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg fixed-dose combination metered dose inhaler (GFF MDI) were investigated in a 28-week safety extension study (PINNACLE-3, NCT01970878) of two randomized controlled Phase III trials (PINNACLE-1 and -2; NCT01854645 and NCT01854658) in subjects with moderate-to-very severe chronic obstructive pulmonary disease (COPD). METHODS Subjects completing 24… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Glycopyrronium/Formoterol: A Review in COPD

VIEW 24 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease

VIEW 5 EXCERPTS
CITES METHODS